Where oncology research meets the people who need it most.
KCLEAGENICS MEDICAL is a specialist oncology CRO serving biopharma sponsors and CROs — Phase I–III trial execution, biospecimen research, site management, and GCP-compliant regulatory support. Our Cancer Care Navigation division operates as a dedicated service for patients, caregivers, and referring clinicians.
For patients with a cancer diagnosis, caregivers, and referring clinicians — helping navigate specialist treatment centres, active trials, and support resources across the US.
A SWOG/Fred Hutch analysis of 11,681 US cancer trials (2008–2024) finds 90% of patient enrolments are in industry-sponsored studies — which heavily favour single-agent drug trials, leaving supportive care, dose de-escalation, and rare cancer research chronically underfunded.
Read the KCLG Analysis →CAR-T, antibody-drug conjugates, bispecific antibodies, PROTACs, radioligand therapy — expert analysis of the oncology breakthroughs reshaping care in 2026.
Understanding which cancers affect the most people guides where research effort is most urgently needed. Our trial portfolio is shaped by this epidemiological reality.
Source: American Cancer Society, 2024
Source: GLOBOCAN / WHO, 2022
KCLEAGENICS MEDICAL delivers Phase I–III trial execution for biopharma sponsors and CROs, with in-house regulatory, site management, and biospecimen operations — so sponsors work with one accountable partner across the evidence lifecycle.
We design and operate Phase I–III trials across oncology and haematology — managing site initiation, protocol adherence, pre-specified endpoints, patient recruitment, and independent safety oversight.
End-to-end biospecimen collection, processing, and management integrated within trial operations — supporting translational research, biomarker discovery, and companion diagnostic development.
GCP / ICH E6(R3)-compliant oversight, systematic evidence synthesis, and submission-ready data packages — delivered by a team with direct FDA regulatory experience.
Our research agenda is shaped by unmet clinical need — focusing on areas where new evidence can meaningfully change patient outcomes today, not in a decade.
Join a Trial →CLL, SLL, AML and lymphoma — exploring novel agents, drug combinations and supportive care strategies.
Biomarker-driven trial design and molecular profiling to match patients with the therapies most likely to benefit them.
Checkpoint inhibitors, CAR-T adjacent therapies and immunotherapy combination regimens across solid tumours.
Investigating the relationship between metabolic health, obesity-related risk, and cancer susceptibility across diverse populations.
FDA approved daraxonrasib today for metastatic pancreatic adenocarcinoma — the first RAS(ON) multi-selective inhibitor covering all KRAS variants. Phase 3 RASolute 302: OS 13.2 vs 6.7 months, ORR 33.2% vs 11.8%, approved 6.5 months ahead of PDUFA deadline.
A snapshot of recent regulatory approvals and research advances reshaping oncology care — and informing how we design and prioritise future trials.
The FDA approved nivolumab in combination with chemotherapy as a first-line treatment for adult and adolescent patients with previously untreated, advanced classical Hodgkin lymphoma — widening options for haematology patients.
Source: FDA Oncology Approvals, 2026
A new PROTAC (proteolysis-targeting chimera) therapy received its first oncology approval — a milestone for precision medicine that opens a new mechanistic class for genomically-driven trial design.
Source: FDA Oncology Approvals, 2026
An all-oral treatment combination was approved for older adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy — a major step for accessibility and quality of life.
Source: FDA Oncology Approvals, 2026
The first immunotherapy combination in over three decades was approved for high-risk non-muscle-invasive bladder cancer, offering a bladder-sparing option for patients who don't respond to standard therapy.
Source: FDA Oncology Approvals, 2026
A landmark review of where oncology research is heading — exploring emerging therapies, earlier detection strategies, and what the evidence now says about improving survival outcomes in one of the most challenging cancers.
Explore Our Insights →Source: YouTube · Pancreatic Cancer Research
Evidence-based commentary, trial updates, and clinical briefings for healthcare professionals and informed patients.
A review of the mechanistic rationale and early clinical data supporting statin co-administration in ibrutinib-treated CLL patients.
A plain-language guide covering informed consent, safety monitoring, your rights as a participant, and what happens at each study visit.
An explanation of how pre-specified statistical analysis plans prevent selective reporting and protect the integrity of trial findings.
"Every day that a proven therapy sits in a journal instead of a clinic, a patient who could have benefited doesn't. Our work exists to close that gap — rigorously, ethically, and urgently."— KCLEAGENICS MEDICAL Research Team
Phase I–III trial execution, site management, biospecimen operations, and GCP-compliant regulatory support — delivered as a single accountable partnership.
Our patient-facing service helps people with a cancer diagnosis access specialist treatment centres, active trials, and caregiver support resources across the US.
We work with oncologists and specialist clinicians to identify eligible patients, support site initiation, and provide full investigator support for ongoing trials.
